相关实验视频
Updated: Sep 18, 2025

07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.6K
对补偿性环素D2反应的能力使得在犬类粘膜黑色素瘤中产生了对特拉美丁尼布的耐药性
Bih-Rong Wei1, Vincenzo Verdi1, Shuling Zhang1
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
bioRxiv : the preprint server for biology
|June 26, 2025
概括
粘膜黑色素瘤细胞可以通过从cyclin D1切换到cyclin D2来抵抗MEK抑制剂,促进增殖. 恢复cyclin D2水平重新使细胞对特拉美替尼治疗具有抗药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 粘膜黑色素瘤 (MM) 是一种具有攻击性的癌症,由于耐药性,治疗选择有限.
- 在Ras/MAPK和PI3K/AKT/mTOR途径中的激活突变在MM中很常见.
- 狗MM模型为研究人类MM的治疗耐药性提供了一个有价值的平台.
研究的目的:
- 调查D型环林在MM中对MEK抑制的抵抗中介作用.
- 阐明促进治疗逃避的补偿信号机制.
- 确定潜在的策略来克服MM的耐药性.
主要方法:
- 利用了五个MM细胞系,对特拉美丁尼布有不同的敏感性.
- 分析了信号通路,增殖,生存和细胞周期进展.
- 使用siRNA和重组过度表达的操纵cyclin D1和D2表达.
主要成果:
- 耐药MM细胞在对特拉美替尼的反应中调节了环素D2,促进了增殖.
- 抑制补偿性环林D2的上调调节恢复了特拉美替尼的敏感性.
- 过度表达环林D2提高了其他敏感的MM细胞的存活率.
结论:
- 从环素D1到环素D2的补偿切换驱动MM对MEK抑制剂的耐药性.
- 准cyclin D2或相关途径可以克服特拉美提尼布耐药性.
- 了解这些抵抗机制对于开发有效的MM疗法至关重要.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K

